Form D · Biotechnology
Allevion Therapeutics, Inc.
Irvine, CA · CIK 0001872608
Offering snapshot reported Mar 26, 2024 · SEC filing
- Reported sold
- $1.48M Offering amount: $1.48M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Mar 12, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 26, 2024 | Initial | $1,475,000 | No comparison | 7 | SEC filing |
| Jul 14, 2021 | Initial | $1,000,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-508685
Source: Form D, filed Mar 26, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dan Dearen | Director |
| Neal Hermanowicz | Executive |
| Shinya Miike | Director |
| Shahram Moaddeb | Director, Executive, Promoter |
| Mahmood Razavi | Director |
| Pintoo Shah | Executive |
| Roy Tanaka | Director |
| Jack Wang | Director |
| Randy Werneth | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
18001 Cowan, Suite L
Irvine, CA, 92614
Irvine, CA, 92614